Clinical Trial Update: A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating AK104 as monotherapy or in combination with axitinib for advanced/metastatic renal cell carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Axitinib (Axitinib)

Snippet

Sponsor: Akeso | Conditions: Renal Cell Carcinoma, First-line Treatment | Phase 2 | Status: ACTIVE_NOT_RECRUITING